Drugs / BI 443651
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03135899 | May 2017 → Feb 2018 | asthma | Boehringer Ingelheim | Completed | Met primary |
| Phase 1 | NCT02976519 | Feb 2017 → Aug 2018 | cystic fibrosis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02706925 | Mar → Jun 2016 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 443651 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02976519 ↗ |
| Route | Inhaled | “Single Rising Inhaled Doses of BI 443651” NCT02706925 ↗ |